Press Releases

- BELLUS now owns 100% of BLU-5937 and related P2X3 antagonist intellectual property with no future payments due - - 4.77 million BELLUS Health common shares issued in consideration - LAVAL, Quebec --(BUSINESS WIRE)--Mar. 25, 2020-- BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (the “Company” or

- BELLUS to own 100% of BLU-5937 and related P2X3 antagonists intellectual property with no future payments due - - 4.77 million BELLUS Health common shares to be issued in consideration - LAVAL, Quebec --(BUSINESS WIRE)--Mar. 23, 2020-- BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (the “Company” or

- On track to report topline data from the RELIEF trial in mid-2020 - LAVAL, Quebec --(BUSINESS WIRE)-- BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (the “Company” or “BELLUS Health”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other

LAVAL, Quebec --(BUSINESS WIRE)-- BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today reported its financial

LAVAL, Quebec --(BUSINESS WIRE)--Feb. 20, 2020-- BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced